Literature DB >> 23846918

Prognostic factors in pancreatic cancer.

Georgios Michael Oikonomopoulos1, Konstantinos N Syrigos, Muhammad Wasif Saif.   

Abstract

Pancreatic cancer is a frequent and lethal disease ranking fourth as a cause of cancer-related death in Western countries. There are patients, though, who respond well to chemotherapy and have a prolonged survival. There is an effort towards identification of specific characteristics of these tumor cells in order to identify those patients who will benefit from chemotherapy and use them as prognostic or predictive factors. This review is an update on the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important developments in this field for pancreatic cancer, as they were reported in Abstracts #4006, #4016, #4046, and #4060 and a discussion is presented about their application in clinical praxis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846918     DOI: 10.6092/1590-8577/1644

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  4 in total

Review 1.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

3.  Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death.

Authors:  Shuya Kasai; Takuya Sasaki; Ayano Watanabe; Masao Nishiya; Shinji Yasuhira; Masahiko Shibazaki; Chihaya Maesawa
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

4.  Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.

Authors:  Xiwen Liao; Ketuan Huang; Rui Huang; Xiaoguang Liu; Chuangye Han; Long Yu; Tingdong Yu; Chengkun Yang; Xiangkun Wang; Tao Peng
Journal:  Onco Targets Ther       Date:  2017-09-12       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.